JaLCDOI 10.18926/AMO/53671
FullText URL 69_5_261.pdf
Author Nojima, Daisuke| Fujimoto, Nobukazu| Kato, Katsuya| Fuchimoto, Yasuko| Kiura, Katsuyuki| Kishimoto, Takumi| Tanimoto, Mitsune|
Abstract We investigated the clinical features of asbestos-induced diffuse pleural thickening (DPT) with severe respiratory compromise. We conducted a retrospective study of consecutive subjects with asbestos-induced DPT. Medical data such as initial symptoms, radiological findings, respiratory function test results, and clinical course were collected and analyzed. There were 24 patients between 2003 and 2012. All were men, and the median age at the development of DPT was 74 years. The top occupational category associated with asbestos exposure was dockyard workers. The median duration of asbestos exposure was 35.0 years, and the median latency from first exposure to the onset of DPT was 49.0 years. There were no significant differences in respiratory function test results between the higher and lower Brinkman index groups or between unilateral and bilateral DPT. Thirteen patients had a history of benign asbestos pleural effusion (BAPE), and the median duration from pleural fluid accumulation to DPT with severe respiratory compromise was 28.4 months. DPT with severe respiratory compromise can develop after a long latency following occupational asbestos exposure and a history of BAPE.
Keywords asbestos pleural thickening MRC dyspnea scale respiratory function test costophrenic angle
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-10
Volume volume69
Issue issue5
Publisher Okayama University Medical School
Start Page 261
End Page 266
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26490022
Web of Science KeyUT 000365519600001
JaLCDOI 10.18926/AMO/32200
FullText URL fulltext.pdf
Author Ohnoshi, Taisuke| Hiraki, Shunkichi| Ueda, Nobuo| Fujii, Masafumi| Machida, Ken-ichi| Ueoka, Hiroshi| Kawahara, Shin| Kozuka, Akira| Kiura, Katsuyuki| Moritaka, Tomonori| Kodani, Tsuyoshi| Kamei, Haruhito| Kimura, Ikuro|
Abstract

Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

Keywords non-small cell lung cancer ifosfamide cisplatin vindesine
Amo Type Article
Publication Title Acta Medica Okayama
Published Date 1991-10
Volume volume45
Issue issue5
Publisher Okayama University Medical School
Start Page 357
End Page 361
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
File Version publisher
Refereed True
PubMed ID 1661559
Web of Science KeyUT A1991GN53800010
FullText URL fulltext20230421-01.pdf figure20230421-01.pdf
Author Nakasuka, Takamasa| Ohashi, Kadoaki| Nishii, Kazuya| Hirabae, Atsuko| Okawa, Sachi| Tomonobu, Nahoko| Takada, Kenji| Ando, Chihiro| Watanabe, Hiromi| Makimoto, Go| Ninomiya, Kiichiro| Fujii, Masanori| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Kumon, Hiromi| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords EGFR mutation Non-small cell lung cancer Antitumor immunity Non-inflamed tumor Ad-SGE-REIC Gene therapy PD-1
Note ©2023 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 License. http://creativecommons.org/licenses/by-nc-nd/4.0/. This is the accepted manuscript version. The formal published version is available at https://doi.org/10.1016/j.lungcan.2023.01.018.| This fulltext file will be available in Apr. 2024.|
Published Date 2023-04
Publication Title Lung Cancer
Volume volume178
Publisher Elsevier BV
Start Page 1
End Page 10
ISSN 0169-5002
NCID AA10785743
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2023 Elsevier B.V.
File Version author
PubMed ID 36753780
DOI 10.1016/j.lungcan.2023.01.018
Web of Science KeyUT 000931976300001
Related Url isVersionOf https://doi.org/10.1016/j.lungcan.2023.01.018
FullText URL fulltext.pdf
Author Nishii, Kazuya| Inoue, Masaaki| Obata, Hideto| Ueda, Yutaka| Kozuki, Toshiyuki| Yamasaki, Masahiro| Moritaka, Tomonori| Awaya, Yoshikazu| Sugimoto, Keisuke| Gemba, Kenichi| Kuyama, Shoichi| Ichikawa, Hirohisa| Shibayama, Takuo| Kubota, Tetsuya| Kodani, Masahiro| Kishino, Daizo| Fujimoto, Nobukazu| Ishikawa, Nobuhisa| Tsubata, Yukari| Ishii, Tomoya| Fujitaka, Kazunori| Hotta, Katsuyuki| Kiura, Katsuyuki|
Keywords Database observational study real world data surveillance treatment
Published Date 2021-01-12
Publication Title Thoracic Cancer
Volume volume12
Issue issue5
Publisher Wiley
Start Page 725
End Page 731
ISSN 1759-7706
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Authors.
File Version publisher
PubMed ID 33434415
DOI 10.1111/1759-7714.13789
Web of Science KeyUT 000606961500001
Related Url isVersionOf https://doi.org/10.1111/1759-7714.13789
FullText URL fulltext.pdf
Author Senoo, Satoru| Miyahara, Nobuaki| Taniguchi, Akihiko| Oda, Naohiro| Itano, Junko| Higo, Hisao| Hara, Naofumi| Watanabe, Hiromi| Kano, Hirohisa| Suwaki, Toshimitsu| Fuchimoto, Yasuko| Kajimoto, Kazuhiro| Ichikawa, Hirohisa| Kudo, Kenichiro| Shibayama, Takuo| Tanimoto, Yasushi| Kuyama, Shoichi| Kanehiro, Arihiko| Maeda, Yoshinobu| Kiura, Katsuyuki| Okayama Respiratory Disease Study Group (ORDSG)|
Published Date 2020-08-27
Publication Title PLoS ONE
Volume volume15
Issue issue8
Publisher Public Library of Science
Start Page e0236935
ISSN 1932-6203
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2020 Senoo et al.
File Version publisher
PubMed ID 32853277
DOI 10.1371/journal.pone.0236935
Web of Science KeyUT 000566948800009
Related Url isVersionOf https://doi.org/10.1371/journal.pone.0236935
FullText URL fulltext20221223-3.pdf NA_Itano_Fig.pdf supl20221223-3.pdf NA_Itano_Supl.pdf
Author Itano, Junko| Taniguchi, Akihiko| Senoo, Satoru| Asada, Noboru| Gion, Yuka| Egusa, Yuria| Guo, Lili| Oda, Naohiro| Araki, Kota| Sato, Yasuharu| Toyooka, Shinichi| Kiura, Katsuyuki| Maeda, Yoshinobu| Miyahara, Nobuaki|
Keywords idiopathic pulmonary fibrosis NPY IL-1 beta; bleomycin bronchial epithelial cells
Note Originally Published in:Itano J, Taniguchi A, Senoo S, Asada N, Gion Y, Egusa Y, Guo L, Oda N, Araki K, Sato Y, Toyooka S, Kiura K, Maeda Y, Miyahara N. Neuropeptide Y Antagonizes Development of Pulmonary Fibrosis through IL-1β Inhibition. Am J Respir Cell Mol Biol. 2022 Dec;67(6):654-665.
DOI: 10.1165/rcmb.2021-0542OC
Copyright © 2022 by the American Thoracic Society
The final publication is available at https://doi.org/10.1165/rcmb.2021-0542OC |
This full-text will be available in Dec. 2023.|
Published Date 2022-12
Publication Title American Journal of Respiratory Cell and Molecular Biology
Volume volume67
Issue issue6
Publisher American Thoracic Society
Start Page 654
End Page 665
ISSN 1044-1549
NCID AA10707251
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2022 by the American Thoracic Society
File Version author
PubMed ID 36122332
DOI 10.1165/rcmb.2021-0542oc
Web of Science KeyUT 000891796900010
Related Url isVersionOf https://doi.org/10.1165/rcmb.2021-0542oc
JaLCDOI 10.18926/AMO/31591
FullText URL fulltext.pdf
Author Ohnoshi, Taisuke| Hiraki, Shunkichi| Fujii, Masafumi| Ueoka, Hiroshi| Yonei, Toshiro| Tamura, Makoto| Moritaka, Tomonori| Mima, Yuchi| Horiguchi, Takashi| Kiura, Katsuyuki| Kamei, Haruhito| Kodani, Tsuyoshi| Hiraki, Yoshio| Kimura, Ikuro|
Abstract

We evaluated the long-term outcome of 148 patients with small cell lung cancer (SCLC) who had been entered into clinical trials of chemotherapy with or without thoracic and prophylactic cranial irradiation (PCI) between 1981 and 1987. Eighteen patients (12%) survived for 2 or more years. With a minimum follow-up of 4.5 years, 10 of the 18 patients who remained disease-free at 2 years are currently alive and free of SCLC. Seven of these 10 patients currently function as they did before diagnosis. However, three suffer from central nervous system changes of varying degrees in severity which appeared 2-3 years after PCI. Eight of the 18 patients who were disease-free at 2 years have died. Two died of isolated relapse in the brain at 3.6 and 4.2 years after initiation of chemotherapy. Five died of other malignancies while continuing their complete response to SCLC; two of non-small cell lung cancer, two of acute myelogenous leukemia, and one of hepatocellular carcinoma. Another patient died of an unrelated disease without any evidence of SCLC. A small but substantial proportion of patients who underwent intensive treatment will achieve long-term survival; however, these patients remain at higher risk for second cancers and late toxicities. Therefore, attention must be directed to defining the safest way to employ such treatment in the management of SCLC.

Keywords small cell lung cancer long-term survivors late relapse toxicities complications
Amo Type Article
Publication Title Acta Medica Okayama
Published Date 1993-06
Volume volume47
Issue issue3
Publisher Okayama University Medical School
Start Page 209
End Page 214
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
File Version publisher
Refereed True
PubMed ID 8397470
Web of Science KeyUT A1993LL12400010
FullText URL fulltext.pdf
Author Morinaga, Takao| Inozume, Takashi| Kawazu, Masahito| Ueda, Youki| Sax, Nicolas| Yamashita, Kazuo| Kawashima, Shusuke| Nagasaki, Joji| Ueno, Toshihide| Lin, Jason| Ohara, Yuuki| Kuwata, Takeshi| Yukami, Hiroki| Kawazoe, Akihito| Shitara, Kohei| Honobe-Tabuchi, Akiko| Ohnuma, Takehiro| Kawamura, Tatsuyoshi| Umeda, Yoshiyasu| Kawahara, Yu| Nakamura, Yasuhiro| Kiniwa, Yukiko| Morita, Ayako| Ichihara, Eiki| Kiura, Katsuyuki| Enokida, Tomohiro| Tahara, Makoto| Hasegawa, Yoshinori| Mano, Hiroyuki| Suzuki, Yutaka| Nishikawa, Hiroyoshi| Togashi, Yosuke|
Published Date 2022-07-28
Publication Title Cancer Research Communications
Volume volume2
Issue issue7
Publisher American Association for Cancer Research
Start Page 739
End Page 753
ISSN 2767-9764
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2022 The Authors
File Version publisher
PubMed ID 36923281
DOI 10.1158/2767-9764.CRC-22-0050
Web of Science KeyUT 001048412300001
Related Url isVersionOf https://doi.org/10.1158/2767-9764.CRC-22-0050
FullText URL fulltext.pdf
Author Taoka, Masataka| Makimoto, Go| Umakoshi, Noriyuki| Ninomiya, Kiichiro| Higo, Hisao| Kato, Yuka| Fujii, Masanori| Kubo, Toshio| Ichihara, Eiki| Ohashi, Kadoaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords Hemoptysis Bronchial artery embolization Endoscopic bronchial occlusion Endobronchial Watanabe Spigot
Published Date 2022
Publication Title Respiratory Medicine Case Reports
Volume volume38
Publisher Elsevier
Start Page 101669
ISSN 2213-0071
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2022 The Authors.
File Version publisher
PubMed ID 35646587
DOI 10.1016/j.rmcr.2022.101669
Web of Science KeyUT 001089212200003
Related Url isVersionOf https://doi.org/10.1016/j.rmcr.2022.101669
FullText URL fulltext.pdf
Author Okawa, Sachi| Rai, Kammei| Fujii, Nobuharu| Gion, Yuka| Ninomiya, Kiichiro| Kato, Yuka| Taniguchi, Akihiko| Kubo, Toshio| Ichihara, Eiki| Ohashi, Kadoaki| Miyahara, Nobuaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords EGFR IgG4-related disease marginal zone lymphoma osimertinib
Published Date 2021-09-01
Publication Title Internal Medicine
Volume volume60
Issue issue17
Publisher The Japanese Society of Internal Medicine
Start Page 2831
End Page 2837
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2021 The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 33775999
DOI 10.2169/internalmedicine.6470-20
Web of Science KeyUT 000695856000020
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.6470-20
FullText URL fulltext.pdf
Author Ichihara, Eiki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords lung cancer interstitial pneumonia
Published Date 2020-01-15
Publication Title Internal Medicine
Volume volume59
Issue issue2
Publisher 日本内科学会
Start Page 163
End Page 167
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language English
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 31534086
DOI 10.2169/internalmedicine.3481-19
NAID 130007785095
Web of Science KeyUT 000507577600002
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.3481-19
JaLCDOI 10.18926/AMO/31553
FullText URL fulltext.pdf
Author Tabata, Masahiro| Ohnoshi, Taisuke| Ueoka, Hiroshi| Kiura, Katsuyuki| Kimura, Ikuro|
Abstract

We report a preliminary study to determine whether MDR1 gene expression level in small cell lung cancer (SCLC) tumors is a useful predictor of tumor response to chemotherapy and patient survival in association with myc amplification in the tumor. We analyzed 18 patients with SCLC receiving adriamycin and etoposide combination chemotherapy between August 1989 and November 1991; 16 males and 2 females, median age of 68 years, and 7 with limited disease and 11 with extensive disease. MDR1 mRNA expression level and myc family gene amplification were simultaneously determined by polymerase chain reaction using transbronchial biopsy specimens which were obtained at diagnosis. Patients with tumors expressing low MDR1 mRNA responded more favorably to chemotherapy than those with tumors expressing high MDRI mRNA, however, the difference in tumor response was statistically not significant (84.6% versus 40%). The overall survival was significantly shorter in the latter than in the former (7.2 months versus 11.7 months; p = 0.023). The survival of the 4 patients with tumor showing myc family gene amplification was almost identical to that of patients with tumors showing no amplification of the gene (8.2 months versus 8.8 months; p = 0.73). Multivariate Cox's regression analysis supports the notion that MDR1 may be a useful independent prognostic factor.

Keywords small cell lung cancer MDR1 mRNA expression myc gene amplification prognostic factor
Amo Type Article
Publication Title Acta Medica Okayama
Published Date 1993-08
Volume volume47
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 248
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
File Version publisher
Refereed True
PubMed ID 8213218
Web of Science KeyUT A1993LV73800004
FullText URL fulltext.pdf
Author Watanabe, Kenta| Katsui, Kuniaki| Sugiyama, Soichiro| Yoshio, Kotaro| Kuroda, Masahiro| Hiraki, Takao| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu|
Keywords Clinical pathology Elderly Non-small cell lung carcinoma Radiosurgery Stereotactic body radiation therapy
Published Date 2021-02-23
Publication Title Radiation Oncology
Volume volume16
Issue issue1
Publisher BMC
Start Page 39
ISSN 1748-717X
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s) 2021.
File Version publisher
PubMed ID 33622369
DOI 10.1186/s13014-021-01769-7
Web of Science KeyUT 000623175000001
Related Url isVersionOf https://doi.org/10.1186/s13014-021-01769-7
Author Hayakawa, Hiromi| Ichihara, Eiki| Ohashi, Kadoaki| Ninomiya, Takashi| Yasugi, Masayuki| Takata, Saburo| Sakai, Katsuya| Matsumoto, Kunio| Takigawa, Nagio| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-11
Publication Title Cancer Science
Volume volume104
Issue issue11
Content Type Journal Article
FullText URL fulltext20231004-03.pdf fig1_20231004-03.pdf fig2_20231004-03.pdf fig3_20231004-03.pdf fig4_20231004-03.pdf fig5_20231004-03.pdf Suppl20231004-03.pdf
Author Kemmotsu, Naoya| Ninomiya, Kiichiro| Kunimasa, Kei| Ishino, Takamasa| Nagasaki, Joji| Otani, Yoshihiro| Michiue, Hiroyuki| Ichihara, Eiki| Ohashi, Kadoaki| Inoue, Takako| Tamiya, Motohiro| Sakai, Kazuko| Ueda, Youki| Dansako, Hiromichi| Nishio, Kazuto| Kiura, Katsuyuki| Date, Isao| Togashi, Yosuke|
Keywords cancer immunotherapy intracranial metastasis intracranial progression memory precursor effector T cell nonsmall-cell lung cancer
Note This is the peer reviewed version of the following article: [Kemmotsu N, Ninomiya K, Kunimasa K, et al. Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies. Int J Cancer. 2024; 154(1): 169-179. doi:10.1002/ijc.34700], which has been published in final form at [https://doi.org/10.1002/ijc.34700]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.| This fulltext file will be available in Aug. 2024.|
Published Date 2023-08-23
Publication Title International Journal of Cancer
Volume volume154
Issue issue1
Publisher Wiley
Start Page 169
End Page 179
ISSN 0020-7136
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2023 UICC.
File Version author
PubMed ID 37611176
DOI 10.1002/ijc.34700
Web of Science KeyUT 001069876600001
Related Url isVersionOf https://doi.org/10.1002/ijc.34700
FullText URL fulltext.pdf
Author Makimoto, Go| Ohashi, Kadoaki| Taniguchi, Kohei| Soh, Junichi| Taniguchi, Akihiko| Miyahara, Nobuaki| Toyooka, Shinichi| Yoshino, Tadashi| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords IgG4-related disease Pleural effusion Adenosine deaminase Pleural biopsy Spontaneous remission
Published Date 2019
Publication Title Respiratory Medicine Case Reports
Volume volume28
Publisher Elsevier
Start Page 100938
ISSN 2213-0071
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2019 The Authors.
File Version publisher
PubMed ID 31667074
DOI 10.1016/j.rmcr.2019.100938
Web of Science KeyUT 000511444900052
Related Url isVersionOf https://doi.org/10.1016/j.rmcr.2019.100938
Author Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2011-09
Publication Title Molecular Cancer Therapeutics
Volume volume10
Issue issue9
Content Type Journal Article
Author Harada, Daijiro| Takigawa, Nagio| Ochi, Nobuaki| Ninomiya, Takashi| Yasugi, Masayuki| Kubo, Toshio| Takeda, Hiromasa| Ichihara, Eiki| Ohashi, Kadoaki| Takata, Saburo| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2012-10
Publication Title Cancer Science
Volume volume103
Issue issue10
Content Type Journal Article
JaLCDOI 10.18926/AMO/46851
FullText URL 65_4_259.pdf
Author Ogata, Yoshiko| Aoe, Keisuke| Hiraki, Akio| Murakami, Kazuo| Kishino, Daizo| Chikamori, Kenichi| Maeda, Tadashi| Ueoka, Hiroshi| Kiura, Katsuyuki| Tanimoto, Mitsune|
Abstract The objective of this study was to evaluate the utility of the determination of adenosine deaminase (ADA) level in pleural fluid for the differential diagnosis between tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) in Japan, a country with intermediate incidence of tuberculosis (TB). We retrospectively reviewed the clinical records of 435 patients with pleural effusion and investigated their pleural ADA levels as determined by an auto analyzer. ROC analysis was also performed. The study included patients with MPE (n=188), TPE (n=124), benign nontuberculous pleural effusion (n=94), and pleural effusion of unknown etiology (n=29). The median ADA level in the TPE group was 70.8U/L, which was significantly higher than that in any other groups (p<0.05). The area under the curve (AUC) in ROC analysis was 0.895. With a cut-off level for ADA of 36U/L, the sensitivity, specificity, positive predictive value, and negative predictive value were 85.5%, 86.5%, 69.7%, and 93.6%, respectively. As many as 9% of patients with lung cancer and 15% of those with mesothelioma were false-positive with this ADA cutoff setting. Although the ADA activity in pleural fluid can help in the diagnosis of TPE, it should be noted that some cases of lung cancer or mesothelioma show high ADA activity in geographical regions with intermediate incidence of TB, in contrast to high prevalence areas.
Keywords pleural effusion adenosine deaminase tuberculosis lung cancer mesothelioma
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2011-08
Volume volume65
Issue issue4
Publisher Okayama University Medical School
Start Page 259
End Page 263
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2011 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 21860532
Web of Science KeyUT 000294236700006
JaLCDOI 10.18926/AMO/31590
FullText URL fulltext.pdf
Author Segawa, Yoshihiko| Ohnoshi, Taisuke| Hiraki, Shunkichi| Ueoka, Hiroshi| Kiura, Katsuyuki| Kamei, Haruhito| Tabata, Masahiro| Shibayama, Takuo| Miyatake, Kazuyo| Genda, ken-ichi| Matsumura, Tadashi| Kimura, Ikuro|
Abstract

In an attempt to elucidate the tumor properties relating to responsiveness to chemotherapy, we examined immunohistochemically the expression of P-glycoprotein (P-gp) and carcinoembryonic antigen (CEA) in small cell lung cancer (SCLC) tumors. Tumor specimens from 33 patients were obtained at the time of diagnosis and relapse. Four patients expressed P-gp in their initial tumors, and 7 others did in recurrent tumors. The overall response rate to chemotherapy of the initial tumors was 75% for P-gp-positive initial tumors and 86% for P-gp-negative tumors, whereas the disease-free and overall survival times were significantly shorter in the former than the latter. Three patients showed CEA in their initial tumors, and 5 others did in recurrent tumors. The patients with CEA-positive initial tumors tended to relapse earlier than those with CEA-negative tumors. In addition, recurrent tumors expressing CEA were resistant to salvage chemotherapy. A clear correlation between CEA expression by tumors and the CEA level in the serum was observed at diagnosis as well as at relapse. These findings indicate that P-gp and/or CEA expression by a tumor and elevated CEA level in the serum may predict refractoriness of the tumor to chemotherapy.

Keywords small cell lung cancer immunohistochemistry drug resistance P-glycoprotein carcinoembryonic antigen
Amo Type Article
Publication Title Acta Medica Okayama
Published Date 1993-06
Volume volume47
Issue issue3
Publisher Okayama University Medical School
Start Page 181
End Page 189
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
File Version publisher
Refereed True
PubMed ID 8104371
Web of Science KeyUT A1993LL12400007